SCHEMBL13700337

SCHEMBL13700337

CC(=O)[C@H]1NCC2[C@@H]1C2(C)C

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
MEN1 O00255 2/20 0.30
KMT2A Q03164 2/20 0.30
MAPK1 P28482 1/20 0.30
TSHR P16473 1/20 0.30
SLC1A2 P43004 1/20 0.30
THPO P40225 1/20 0.30
ALDH1A1 P00352 1/20 0.30
LMNA P02545 1/20 0.30
HPGD P15428 1/20 0.30
GRIK1 P39086 1/20 0.30
GRM5 P41594 1/20 0.30
GRIA1 P42261 1/20 0.30
GRIA2 P42262 1/20 0.30
GRIA3 P42263 1/20 0.30
GRIA4 P48058 1/20 0.30
BLM P54132 1/20 0.30
GRIK2 Q13002 1/20 0.30
GRIK3 Q13003 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6346520 1.00 PKM (0.30) PKMSMN1; SMN2MEN1KMT2AMAPK1
SCHEMBL13103459 1.00 PKM (0.30) PKMSMN1; SMN2MEN1KMT2AMAPK1
SCHEMBL13679529 0.83
SCHEMBL28063284 0.82 PKM (0.43) PKMSMN1; SMN2MEN1KMT2AMAPK1
SCHEMBL31289285 0.82 PKM (0.43) PKMSMN1; SMN2MEN1KMT2AMAPK1
SCHEMBL1592286 0.82 PKM (0.43) PKMSMN1; SMN2MEN1KMT2AMAPK1
SCHEMBL1592240 0.82 PKM (0.43) PKMSMN1; SMN2MEN1KMT2AMAPK1
SCHEMBL27788944 0.82 PKM (0.43) PKMSMN1; SMN2MEN1KMT2AMAPK1
SCHEMBL16326618 0.82 PKM (0.43) PKMSMN1; SMN2MEN1KMT2AMAPK1
SCHEMBL24108977 0.80 FPR2 (0.30)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090240063-A1 Process For The Preparation Of 6,6-Dimethyl-3-Azabicyclo-[3.1.0]-Hexane Compounds ... MERCK SHARP & DOHME CORP. 2009-09-24 US disclosed
US-7326795-B2 Process and intermediates for the preparation of (1R,2S,5S)-3-azabicyclo[3,1,0]hexane-2-carboxamide, N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2S)-2-[[[1,1-dimethylethyl]amino]carbonylamino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl SCHERING CORPORATION (US) 2008-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240063-A1 Process For The Preparation Of 6,6-Dimethyl-3-Azabicyclo-[3.1.0]-Hexane Compounds ... TMT1A, HDHD5, TET1 PKM 3958/4885SMN1; SMN2 3941/4885MEN1 4365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.